Abstract
PCN100 - Cost-Effectiveness Model of Pertuzumab in Combination with Trastuzumab and Docetaxel Compared with Trastuzumab in Combination with Docetaxel for the 1st Line Treatment of HER2+ Metastatic Breast Cancer in Colombia
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have